Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Lund

Showing results (631-640 of 826) with videos related to

Pageof 83
Sort By:
ESC Heart Failure|July 30, 2024
Rates and predictors of cardiovascular and non-cardiovascular outcomes in heart failure with preserved ejection fractionAngiza Shahim, Erwan Donal, Camilla Hage, et al.
Circulation. Heart Failure|May 14, 2024
Generalizable Approach to Quantifying Guideline-Directed Medical TherapyMirza S Khan, Paul S Chan, Charles F Sherrod, et al.
Journal of Thrombosis and Thrombolysis|February 20, 2017
Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trialAlma Rut Oskarsdóttir, Brynja R Gudmundsdottir, Olafur S Indridason, et al.
Blood Advances|January 4, 2018
Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based studySigrun Thorsteinsdottir, Sigrun H Lund, Ebba K Lindqvist, et al.
American Heart Journal|February 8, 2020
Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipientsKenneth C Bilchick, Yongfei Wang, Jeptha P Curtis, et al.
European Journal of Heart Failure|February 18, 2021
Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure RegistryPeter M Becher, Benedikt Schrage, Giulia Ferrannini, et al.
Circulation. Heart Failure|December 16, 2017
Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study Heart Failure Community SurveillanceTonje Thorvaldsen, Brian L Claggett, Amil Shah, et al.
European Journal of Heart Failure|February 13, 2018
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrumLars H Lund, Brian Claggett, Jiankang Liu, et al.
European Journal of Heart Failure|October 5, 2023
Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: Data from Swedish Heart Failure RegistryFederica Guidetti, Lars H Lund, Lina Benson, et al.
Eclinicalmedicine|September 25, 2023
Changing health related quality of life and outcomes in heart failure by age, sex and subtypeClaire A Lawson, Lina Benson, Iain Squire, et al.
Pageof 83

Showing results (631-640 of 826) with videos related to

Sort By:
Pageof 83
ESC Heart Failure|July 30, 2024
Rates and predictors of cardiovascular and non-cardiovascular outcomes in heart failure with preserved ejection fractionAngiza Shahim, Erwan Donal, Camilla Hage, et al.
Circulation. Heart Failure|May 14, 2024
Generalizable Approach to Quantifying Guideline-Directed Medical TherapyMirza S Khan, Paul S Chan, Charles F Sherrod, et al.
Journal of Thrombosis and Thrombolysis|February 20, 2017
Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trialAlma Rut Oskarsdóttir, Brynja R Gudmundsdottir, Olafur S Indridason, et al.
Blood Advances|January 4, 2018
Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based studySigrun Thorsteinsdottir, Sigrun H Lund, Ebba K Lindqvist, et al.
American Heart Journal|February 8, 2020
Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipientsKenneth C Bilchick, Yongfei Wang, Jeptha P Curtis, et al.
European Journal of Heart Failure|February 18, 2021
Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure RegistryPeter M Becher, Benedikt Schrage, Giulia Ferrannini, et al.
Circulation. Heart Failure|December 16, 2017
Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study Heart Failure Community SurveillanceTonje Thorvaldsen, Brian L Claggett, Amil Shah, et al.
European Journal of Heart Failure|February 13, 2018
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrumLars H Lund, Brian Claggett, Jiankang Liu, et al.
European Journal of Heart Failure|October 5, 2023
Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: Data from Swedish Heart Failure RegistryFederica Guidetti, Lars H Lund, Lina Benson, et al.
Eclinicalmedicine|September 25, 2023
Changing health related quality of life and outcomes in heart failure by age, sex and subtypeClaire A Lawson, Lina Benson, Iain Squire, et al.
Pageof 83